FindMyKOL
Clinical trialNCT04043195Active, not recruitingPhase 1/2Interventional

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

NCT04043195 is a phase 1/2 interventional trial sponsored by Hatim Husain. As of 21 Nov 2026, it is active and no longer recruiting. It studies Ipilimumab, Nivolumab and Oxaliplatin in Advanced NSCLC. The registry lists an enrollment of 30 participants at 1 site in 1 country. The registry lists a start date of 14 Aug 2019 and a primary completion date of 31 Dec 2025.

SponsorHatim HusainEnrollment30Advanced NSCLC
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04043195
FieldValue
Registry IDNCT04043195
StatusActive not recruiting
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorHatim Husain
Enrollment30
Registered sites1
Countries1
ConditionsAdvanced NSCLC
DrugsIpilimumab, Nivolumab and Oxaliplatin
Start14 Aug 2019
Primary completion31 Dec 2025
Study completion31 Dec 2026
Last update posted28 May 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site
  • Uc San Diego Moores Cancer Center

    La Jolla

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 siteCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04043195

Each answer restates registry values shown on this page.

What is NCT04043195?

NCT04043195 is a phase 1/2 interventional trial sponsored by Hatim Husain. It studies Ipilimumab, Nivolumab and Oxaliplatin in Advanced NSCLC.

Is NCT04043195 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04043195?

The registry names Hatim Husain (principal investigator, University of California, San Diego) as the overall official.

Where does NCT04043195 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04043195 study?

The registered drug and biological interventions are Ipilimumab, Nivolumab and Oxaliplatin.

When is NCT04043195 expected to complete?

The registry lists a primary completion date of 31 Dec 2025 and a study completion date of 31 Dec 2026. The sponsor last updated the record on 28 May 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.